Immunotherapy-Ineligibility Flag for Metastatic TNBC

An EHR-embedded triage tool that screens every new advanced triple-negative breast cancer diagnosis for PD-1/PD-L1 inhibitor ineligibility (PD-L1 CPS under 10, prior immunotherapy, or autoimmune comorbidity) and prompts routing to first-line sacituzumab govitecan instead of default single-agent chemotherapy.